Form 8-K HERCULES TECHNOLOGY GROW For: Oct 02
Tweet
Share
E-mail
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 2, 2015
Hercules Technology Growth Capital, Inc.
(Exact name of registrant as specified in its charter)
| Maryland | 814-00702 | 74-3113410 | ||
| (State or other jurisdiction of incorporation) |
(Commission File No.) |
(I.R.S. Employer Identification No.) |
| 400 Hamilton Ave., Suite 310 Palo Alto, CA |
94301 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (650) 289-3060
Not Applicable
(Former name or address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events |
On October 2, 2015, Hercules Technology Growth Capital, Inc. issued a press release congratulating Edge Therapeutics, Inc. on its initial public offering.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
99.1 Press Release dated October 2, 2015.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HERCULES TECHNOLOGY GROWTH CAPITAL, INC. | ||||||||
| October 2, 2015 | ||||||||
| By: | /s/ Manuel A. Henriquez | |||||||
| Manuel A. Henriquez | ||||||||
| Chief Executive Officer | ||||||||
EXHIBIT INDEX
| Exhibit |
Description of Exhibits | |
| 99.1 | Press Release dated October 2, 2015 | |
Exhibit 99.1
Hercules Congratulates Portfolio Company Edge Therapeutics on Its Initial Public Offering
| • | Twelve (12) Hercules Portfolio Companies Completed or Announced IPO and M&A Liquidity Events Year-to-Date 2015 |
| • | Hercules Currently Has Six (6) Portfolio Companies in IPO Registration |
| • | Hercules Holds Warrant Positions in 131 Pre-IPO or M&A Portfolio Companies, as of June 30, 2015, Representing Potential Future Additional Returns to Investors* |
| • | Hercules Holds Equity Positions in 47 Pre-IPO or M&A Portfolio Companies, as of June 30, 2015, Representing Potential Future Additional Returns to Investors* |
PALO ALTO, Calif., October 2, 2015 - Hercules Technology Growth Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading specialty finance company to innovative, high-growth venture capital-backed companies, today noted that its portfolio company, Edge Therapeutics, Inc., completed its initial public offering (“IPO”) on October 1, 2015. Edge Therapeutics, a clinical-stage biotechnology company developing therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions, included approximately 7.3 million shares of its common stock at $11.00 per share in the offering, raising approximately $80 million. Shares of the company are trading on the NASDAQ Global Market under the symbol “EDGE.”
Hercules initially committed $10 million in venture debt financing to Edge Therapeutics in August 2014.
As of October 1, 2015, Hercules currently has six (6) additional portfolio companies who have either publicly or confidentially filed Form S-1 Registration Statements with the SEC in contemplation of a potential IPO. However, there can be no assurances that these companies will complete their IPOs in a timely manner or at all.
| • | Gelesis, Inc. |
| • | Cerecor Inc. |
| • | Four (4) companies filed confidentially under the JOBS Act |
| * | Not all companies will go public or complete an M&A event. |
About Hercules Technology Growth Capital, Inc.
Hercules Technology Growth Capital, Inc. (NYSE: HTGC) (“Hercules”) is the leading specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in the technology, biotechnology, life sciences, healthcare, and energy & renewable technology industries. Since inception (December 2003), Hercules has committed more than $5.5 billion to over 325 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. Companies interested in learning more about financing opportunities should contact [email protected], or call 650.289.3060.
Hercules’ common stock trades on the New York Stock Exchange (NYSE) under the ticker symbol “HTGC.”
In addition, Hercules has three outstanding bond issuances of 7.00% Notes due April 2019, 7.00% Notes due September 2019, and 6.25% Notes due July 2024, which trade on the NYSE under the symbols “HTGZ,” “HTGY,” and “HTGX,” respectively.
Forward-Looking Statements:
The information disclosed in this release is made as of the date hereof and reflects Hercules most current assessment of its historical financial performance. Actual financial results filed with the Securities and Exchange Commission may differ from those contained herein due to timing delays between the date of this release and confirmation of final audit results. These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties, including the uncertainties surrounding the current market volatility, and other factors we identify from time to time in our filings with the Securities and Exchange Commission. Although we believe that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this release are made as of the date hereof, and Hercules assumes no obligation to update the forward-looking statements for subsequent events.
Contact:
Michael Hara
Investor Relations and Corporate Communications
Hercules Technology Growth Capital, Inc.
650-433-5578 HT-HN
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hercules Capital Announces Date for Release of First Quarter 2024 Financial Results and Conference Call
- ROSEN, THE FIRST FILING FIRM, Encourages Sonder Holdings Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – SOND
- ROSEN, TRUSTED INVESTOR COUNSEL, Encourages The Chemours Company Investors to Secure Counsel Before Important Deadline in Securities Class Action – CC
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
